ITEM VIEW

Stereotactic proton beam therapy of skull base meningiomas

dc.contributor.authorVernimmen F.J.
dc.contributor.authorHarris J.K.
dc.contributor.authorWilson J.A.
dc.contributor.authorMelvill R.
dc.contributor.authorSmit B.J.
dc.contributor.authorSlabbert J.P.
dc.date.accessioned2011-05-15T16:16:44Z
dc.date.available2011-05-15T16:16:44Z
dc.date.issued2001
dc.identifier.citationInternational Journal of Radiation Oncology Biology Physics
dc.identifier.citation49
dc.identifier.citation1
dc.identifier.issn03603016
dc.identifier.other10.1016/S0360-3016(00)01457-7
dc.identifier.urihttp://hdl.handle.net/10019.1/13915
dc.description.abstractPurpose: To review outcomes for patients with skull base meningiomas treated using the stereotactic proton beam at the National Accelerator Center (NAC), Republic of South Africa. Methods and Materials: Since 1993, 27 patients with intracranial meningiomas have been treated stereotactically with protons at NAC. Of those, 23 were located on the skull base, were large or had complex shapes, and were treated with radical intent. Both stereotactic radiotherapy (SRT, 16 or more fractions) and hypofractionated stereotactic radiotherapy (HSRT, 3 fractions) were used. Eighteen patients underwent proton HSRT, while 5 patients were treated with SRT. The mean target volume for the HSRT group was 15.6 cm3 (range 2.6-63 cm3). The mean ICRU reference dose was 20.3 cobalt Gray equivalent (CGyE), and the mean minimum planning target dose was 16.3 CGyE. The mean clinical and radiologic follow-up periods were 40 and 31 months respectively. The mean volume in the SRT group was 43.7 cm3, with ICRU reference doses ranging from 54 CGyE in 27 fractions to 61.6 CGyE in 16 fractions. Results: In the HSRT group, 16/18 (89%) of patients remained clinically stable or improved, while 2/18 (11%) deteriorated. Radiologic control was achieved in 88% of patients, while 2 patients had a marginal failure. Among the 5 SRT patients, 2 were clinically better, and 3 remained stable. All SRT patients achieved radiologic control. Three patients (13%), 2 of them in the HSRT group, suffered permanent neurologic deficits. Analyzing different dose/fractionation schedules, an α/β value of 3.7 Gy for meningiomas is estimated. Conclusion: Proton irradiation is effective and safe in controlling large and complex-shaped skull base meningiomas. Copyright © 2001 Elsevier Science Inc.
dc.subjectcobalt
dc.subjectproton
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectbeam therapy
dc.subjectclinical article
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectintracranial tumor
dc.subjectmale
dc.subjectmeningioma
dc.subjectneurologic disease
dc.subjectpriority journal
dc.subjectradiation dose fractionation
dc.subjectradiosurgery
dc.subjectskull base
dc.subjectSouth Africa
dc.subjectstereotaxis
dc.subjecttreatment outcome
dc.subjecttumor localization
dc.subjectAdult
dc.subjectAged
dc.subjectCranial Nerve Diseases
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMeningeal Neoplasms
dc.subjectMeningioma
dc.subjectMiddle Aged
dc.subjectProtons
dc.subjectRadiosurgery
dc.subjectSkull Base
dc.subjectTreatment Outcome
dc.titleStereotactic proton beam therapy of skull base meningiomas
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW